For US residents only.

GLEEVEC Support Continues

For over fifteen years, GLEEVEC® (imatinib mesylate) tablets has supported patients and is proud to continue providing that support today. 

Learn more about GLEEVEC support, including how some patients may be eligible for co-pay or other financial assistance.

Important Information

GLEEVEC® (imatinib mesylate) is available only by prescription.

 

GLEEVEC tablets are indicated for:

 

  • Newly diagnosed adult and pediatric patients with Philadelphia chromosome-positive chr...

See More
Important Safety Information, including Boxed WARNING:

What is the most important information I should know about TASIGNA® (nilotinib)?

TASIGNA can cause a possible life-threatening heart problem called QTc prolongation. QTc prolongation causes an irr...

See More
Approved Uses:

TASIGNA is a prescription medicine used to treat adults who have:

  • Newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. The effectiveness of TASIGNA in these patients is based on a study that measured 2 types of response to treatment (c...
See More

TASIGNA® (nilotinib) Capsules Support Starts Here

If you are no longer benefiting from, or are not tolerating GLEEVEC for the treatment of Ph+ CML in chronic phase, your doctor may recommend changing to TASIGNA® (nilotinib) capsules.

Learn about a free 3-month trial voucher for patients who are new to TASIGNA.

IMPORTANT SAFETY INFORMATION ABOUT TASIGNA® (nilotinib) Capsules

QTc Prolongation and Sudden Death: TASIGNA can cause QTc prolongation, a possibly life-threatening heart problem. QTc prolongation causes an irregular heartbeat, which may lead to sudden death. Call y...

See More
learn more about

How GLEEVEC Works

If you have been prescribed GLEEVEC, it is important to understand treatment, what the benefits and risks may be, and how to take this medication.

Learn More
save with our

GLEEVEC Co-Pay Card

See if you’re eligible for immediate co-pay savings on your next prescription.

Learn More